Насонова, В. А. Новые данные о клинической эффективности и переносимости мелоксикама (мовалиса) [Text] / В. А. Насонова> // Терапевтический архив. - 1999. - Т. 71, № 11. - С. 45-48 Rubrics: Мелоксикам (Мовалис)--тер прим--фарм MeSH-main: ЛЕКАРСТВ АПРОБИРУЕМЫХ ПРИМЕНЕНИЕ -- INVESTIGATIONAL NEW DRUG APPLICATION (методы) There are no free copies |
Malchenko, О. V. In-depth investigation of analgesic activity of N-(4-methoxybenzyl)-4-methyl-2.2-dioxo-1H-2 λ6.1-benzothiazine-3-carboxamide derivate on different models of pain perception [Text] / О. V. Malchenko> // Biomedical and Biosocial Anthropology. - 2021. - № 42. - С. 57-63. - Bibliogr. at the end of the art. Rubrics: Диклофенак--животное--тер прим Мелоксикам (Мовалис)--тер прим--фарм MeSH-main: БОЛЕЗНЬ, МОДЕЛИ НА ЖИВОТНЫХ -- DISEASE MODELS, ANIMAL ДИАБЕТИЧЕСКИЕ НЕВРОПАТИИ -- DIABETIC NEUROPATHIES (патофизиология, этиология) АРТРИТ ЭКСПЕРИМЕНТАЛЬНЫЙ -- ARTHRITIS, EXPERIMENTAL (патофизиология, этиология) БЕНЗОАТЫ -- BENZOATES (анализ) КАРБОНОВЫЕ КИСЛОТЫ -- CARBOXYLIC ACIDS (анализ) ДИАГРАММЫ -- CHARTS ТАБЛИЦЫ -- TABLES Annotation: Among N-(4-methoxybenzyl)-4-methyl-2.2-dioxo-1H-2 λ6.1-benzothiazine-3-carboxamide derivates, the compound methoxybenzyl-amide derivative 4-methyl-2.2-dioxo-1H-2λ6.1-benzothiazine-3-carboxylic acid (compound NI-9) with pronounced analgesic and anti-inflammatory activities, which was superior to those of diclofenac and lornoxicam in the model of carrageenan edema. The aim of the study was to investigate the analgesic effect of benzothiazine-3-carboxamide derivative on different models of somatic and neuropathic pain syndromes. The study was performed on 91 male Wistar rats. Compound NI-9 and reference drugs meloxicam, diclofenac and gabapentin were administered intragastrically at doses of 3, 5, 8 and 5 mg/kg, respectively, corresponding to their ED50 in analgesic activity. Acetic spasms in mice, a model of thermal irritation of the tail flick in rats, as well as adjuvant arthritis and diabetic polyneuropathy were selected as models of pain syndromes. The results were processed in the program STATISTICA 10.0 using non-parametric methods. The results showed that methoxybenzyl-amide derivative 4-methyl-2.2-dioxo-1H-2λ6.1-benzothiazine-3-carboxylic acid (compound NI-9) has a pronounced analgesic effect on various models of pain syndromes, both somatic and inflammatory. and of neurogenic origin. The analgesic activity of the compound NI-9 in the model of acetic acid cramps in mice and thermal irritation in rats was 38.09 and 49.75 %, respectively, which was higher than that of meloxicam (36.73 and 45.68 %), and inferior to diclofenac (41.95 and 55.95 %). In the model of the systemic inflammatory process (adjuvant arthritis), the analgesic effect of NI-9 was statistically superior to meloxicam and diclofenac (43.32 % vs. 26.26 and 33.69 %). In a model of neuropathic pain syndrome (diabetic neuropathy), the analgesic effect of methoxybenzyl-amide derivative 4-methyl-2.2-dioxo-1H-2λ6.1-benzothiazine-3-carboxylic acid was greater than meloxicam (18.96 vs. 13.34 %), but this figure was lower than that of gaapentin (20.83 %). Further in-depth study of its pharmacodynamics and toxicity will be the theoretical basis for the development on the basis of this biologically active compound of the original drug with analgesic and anti-inflammatory activities There are no free copies |